Aktuellt
SENASTE
Redeye leaves its view on Xspray's Q2 report and expects the second half of 2021 to be eventful for the company. Notable events include a BE study readout for the "C-formulation" and submission to FDA under the 505(b)(2) procedure for its improved HyNap-Dasa. Our base case remains SEK 185.
LÄS MER
